On Thursday, the FDA approved Elanco Animal Health Incorporated’s (NYSE:ELAN) Zenrelia, a once-daily oral JAK inhibitor for ...

The canine atopic dermatitis treatment market is set to experience notable growth, with an expected increase from USD ...

Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...

Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...

The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The oral drug, Zenrelia, aims to control pruritus, or itching, associated with allergic dermatitis and to control atopic ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...